These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2920497)

  • 1. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.
    Ratain MJ; Schilsky RL; Choi KE; Guarnieri C; Grimmer D; Vogelzang NJ; Senekjian E; Liebner MA
    Clin Pharmacol Ther; 1989 Mar; 45(3):226-33. PubMed ID: 2920497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling interpatient pharmacodynamic variability of etoposide.
    Mick R; Ratain MJ
    J Natl Cancer Inst; 1991 Nov; 83(21):1560-4. PubMed ID: 1960753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.
    Ratain MJ; Mick R; Schilsky RL; Vogelzang NJ; Berezin F
    J Clin Oncol; 1991 Aug; 9(8):1480-6. PubMed ID: 2072147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic modeling of prolonged administration of etoposide.
    Minami H; Ratain MJ; Ando Y; Shimokata K
    Cancer Chemother Pharmacol; 1996; 39(1-2):61-6. PubMed ID: 8995500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
    Robert F; Chen S; Miller AA; Lee BC; Molthrop DC; Wheeler RH
    Cancer Chemother Pharmacol; 1996; 38(5):459-65. PubMed ID: 8765440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics of etoposide short-term infusions within the scope of the GPOH therapy protocol].
    Boos J; Real E; Schulze-Westhoff P; Pröbsting B; Wolff J; Jürgens H
    Klin Padiatr; 1993; 205(4):288-94. PubMed ID: 8377449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
    Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
    Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
    Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer.
    Joel SP; Ellis P; O'Byrne K; Papamichael D; Hall M; Penson R; Nicholls S; O'Donnell C; Constantinou A; Woodhull J; Nicholson M; Smith I; Talbot D; Slevin M
    J Clin Oncol; 1996 Jun; 14(6):1903-12. PubMed ID: 8656259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer.
    Minami H; Shimokata K; Saka H; Saito H; Ando Y; Senda K; Nomura F; Sakai S
    J Clin Oncol; 1993 Aug; 11(8):1602-8. PubMed ID: 8336196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic optimisation of treatment with oral etoposide.
    Toffoli G; Corona G; Basso B; Boiocchi M
    Clin Pharmacokinet; 2004; 43(7):441-66. PubMed ID: 15139794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 days.
    van der Gaast A; Vlastuin M; Kok TC; Splinter TA
    Semin Oncol; 1992 Dec; 19(6 Suppl 14):8-12. PubMed ID: 1488657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical and pharmacokinetic study of oral etoposide phosphate.
    Sessa C; Zucchetti M; Cerny T; Pagani O; Cavalli F; De Fusco M; De Jong J; Gentili D; McDaniel C; Prins C
    J Clin Oncol; 1995 Jan; 13(1):200-9. PubMed ID: 7799021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.
    Clark PI; Slevin ML; Joel SP; Osborne RJ; Talbot DI; Johnson PW; Reznek R; Masud T; Gregory W; Wrigley PF
    J Clin Oncol; 1994 Jul; 12(7):1427-35. PubMed ID: 8021734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
    Kroschinsky FP; Friedrichsen K; Mueller J; Pursche S; Haenel M; Prondzinsky R; Ehninger G; Schleyer E
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):785-90. PubMed ID: 17579865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.
    Miller AA; Tolley EA; Niell HB
    Clin Cancer Res; 1998 Jul; 4(7):1705-10. PubMed ID: 9676845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.
    Slevin ML; Clark PI; Joel SP; Malik S; Osborne RJ; Gregory WM; Lowe DG; Reznek RH; Wrigley PF
    J Clin Oncol; 1989 Sep; 7(9):1333-40. PubMed ID: 2549204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients.
    Kaul S; Srinivas NR; Igwemezie LN; Barbhaiya RH
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):15-22. PubMed ID: 8996571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.